BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:VERVE-201 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of VERVE-201\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06451770-1074@assetmemo.bio
DTSTAMP:20261121T005844Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:VERVE-201: Phase 1 readout est. (NCT06451770)
DESCRIPTION:VERVE-201\, phase 1\, Atherosclerotic Cardiovascular Disease.\n
 Study: Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipide
 mia\nEstimated primary completion: December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/verve-201#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06451770
URL:https://assetmemo.bio/drug/verve-201#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
